20 related articles for article (PubMed ID: 36730890)
1. MYC amplifications are common events in childhood osteosarcoma.
De Noon S; Ijaz J; Coorens TH; Amary F; Ye H; Strobl A; Lyskjaer I; Flanagan AM; Behjati S
J Pathol Clin Res; 2021 Sep; 7(5):425-431. PubMed ID: 33969640
[TBL] [Abstract][Full Text] [Related]
2. WEE1i-ATRi combination therapy: a promising low-dose treatment for
Goehring L; Huang TT
Cell Rep Med; 2021 Sep; 2(9):100402. PubMed ID: 34622238
[No Abstract] [Full Text] [Related]
3. CDK2 regulates collapsed replication fork repair in CCNE1-amplified ovarian cancer cells via homologous recombination.
Brown VE; Moore SL; Chen M; House N; Ramsden P; Wu HJ; Ribich S; Grassian AR; Choi YJ
NAR Cancer; 2023 Sep; 5(3):zcad039. PubMed ID: 37519629
[No Abstract] [Full Text] [Related]
4. Clinical and translational advances in ovarian cancer therapy.
Konstantinopoulos PA; Matulonis UA
Nat Cancer; 2023 Sep; 4(9):1239-1257. PubMed ID: 37653142
[TBL] [Abstract][Full Text] [Related]
5. Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.
Etemadmoghadam D; Au-Yeung G; Wall M; Mitchell C; Kansara M; Loehrer E; Batzios C; George J; Ftouni S; Weir BA; Carter S; Gresshoff I; Mileshkin L; Rischin D; Hahn WC; Waring PM; Getz G; Cullinane C; Campbell LJ; Bowtell DD
Clin Cancer Res; 2013 Nov; 19(21):5960-71. PubMed ID: 24004674
[TBL] [Abstract][Full Text] [Related]
6. CCNE1 amplification is associated with liver metastasis in gastric carcinoma.
Kim B; Shin HC; Heo YJ; Ha SY; Jang KT; Kim ST; Kang WK; Lee J; Kim KM
Pathol Res Pract; 2019 Aug; 215(8):152434. PubMed ID: 31178228
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes.
Noske A; Henricksen LA; LaFleur B; Zimmermann AK; Tubbs A; Singh S; Storz M; Fink D; Moch H
Exp Mol Pathol; 2015 Feb; 98(1):47-54. PubMed ID: 25527175
[TBL] [Abstract][Full Text] [Related]
8. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.
Nakayama N; Nakayama K; Shamima Y; Ishikawa M; Katagiri A; Iida K; Miyazaki K
Cancer; 2010 Jun; 116(11):2621-34. PubMed ID: 20336784
[TBL] [Abstract][Full Text] [Related]
9. Detection of CCNE1/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endometrial cancer.
Noske A; Brandt S; Valtcheva N; Wagner U; Zhong Q; Bellini E; Fink D; Obermann EC; Moch H; Wild PJ
Oncotarget; 2017 Feb; 8(9):14794-14805. PubMed ID: 27582547
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences.
Yao S; Meric-Bernstam F; Hong D; Janku F; Naing A; Piha-Paul SA; Tsimberidou AM; Karp D; Subbiah V; Yap TA; Ahnert JR; Pant S; Dumbrava EEI; Wathoo C; Campbell E; Yu L; Yamamura Y; Fu S
Sci Rep; 2022 May; 12(1):8701. PubMed ID: 35610322
[TBL] [Abstract][Full Text] [Related]
11.
Au-Yeung G; Mileshkin L; Bowtell DDL
J Clin Oncol; 2023 Mar; 41(9):1770-1773. PubMed ID: 36730890
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
